Genetic or pharmacologic inhibition of ADAR1 in preclinical models restores interferon production, heightens natural killer (NK) and T-cell infiltration, and synergizes with anti-PD-1 therapy to drive durable tumor regression (12). Here, ADAR is linked to neoplasm.